Uppsala, Sweden and Oxford, UK, 28 March 2018: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced Oxford BioMedica® plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, has invested in two Gyrolab xPlore™ systems. This is the first time the Gyrolab technology has been applied within the gene and cell therapy area.
Gene and cell therapy has the potential to transform medicine, providing long-term, and potentially curative, treatment options for a wide range of diseases. Several highly promising cell and gene therapies have been launched recently, including GSK's Strimvelis™ and Novartis’ Kymriah™. Oxford BioMedica’s unique LentiVector® enabled platform has been used to create a valuable portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Company has strong partnerships with Novartis, Bioverativ, Orchard Therapeutics and Immune Design, and has licensed product rights to Sanofi and patent licenses to GSK.
Relative to the pipeline of monoclonal antibody therapies, gene and cell therapy programs are in an earlier stage of development with over 75% in discovery or pre-clinical stages. Gyrolab xPlore offers the ability to develop immunoassays more quickly and increase data quality with reduced hands-on time, reliably and precisely in every phase of biotherapeutic product development.
Gyros Protein Technologies will also work with Oxford BioMedica to assist in the development of key assays for the company.
Dan Calvo, Chief Executive Officer of Gyros Protein Technologies, commented: “The majority of the world’s leading biopharmaceutical companies and CROs now use Gyrolab technology in discovery, pre-clinical and clinical development, and bioprocess of monoclonal antibody therapies. We are delighted that this is now extended to the exciting field of gene and cell therapies. We look forward to supporting Oxford BioMedica in furthering the impact of its LentiVector® enabled platform.”
John Dawson, Chief Executive Officer of Oxford BioMedica, said: “Oxford BioMedica is recognised as a world leader in the field of development and manufacturing of lentiviral vectors, with the goal to develop and commercialise breakthrough gene- and cell-based medicines that improve the lives of patients. Working with industry-leading technology, such as the Gyrolab xPlore, is essential as we work toward achieving these goals.”
Notes to editors
For Gyros Protein Technologies:
Tel: +44(0)7787 502 947
For Oxford BioMedica plc:
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton
Consilium Strategic Communications
Tel: +44 (0)20 3709 5700
About Gyros Protein Technologies
Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low- to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high-performance nanoliter-scale immunoassay platforms, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 300 people. Further information is available at www.oxfordbiomedica.co.uk.